1-7 of 7
Edward J. Olhava, PhD
Close
Sort by
Journal Articles

Pediatric Dose Determinations for the Phase I Study of the DOT1L Inhibitor, EPZ-5676, in MLL-r Acute Leukemia: Leveraging Early Clinical Data in Adults through Physiologically-Based Pharmacokinetic Modeling

Nigel J Waters, PhD, Blythe Thomson, MD, Iain Gardner, PhD, Trevor N Johnson, PhD, Edward J Olhava, PhD, Roy M Pollock, PhD, Michelle Legler, MSHS, Robert A Copeland, PhD, Eric E Hedrick, MD
Journal: Blood
Blood (2014) 124 (21): 3619.
https://doi.org/10.1182/blood.V124.21.3619.3619
Published: 2014
Journal Articles

DOT1L Inhibitor EPZ-5676 Displays Synergistic Antiproliferative Activity in Combination with Standard of Care Drugs or DNA Hypomethylating Agents in MLL -Rearranged Leukemia Cells

Christine R Klaus, Scott R. Daigle, PhD, Dorothy Iwanowics, L. Danielle Johnston, Carly A Therkelsen, Jesse J Smith, PhD, Mikel P Moyer, PhD, Robert A. Copeland, PhD, Edward J Olhava, PhD, Margaret Porter Scott, PhD, Roy M. Pollock, PhD, Alejandra Raimondi
Journal: Blood
Blood (2013) 122 (21): 3930.
https://doi.org/10.1182/blood.V122.21.3930.3930
Published: 2013
Journal Articles

Myeloid Leukemia Cells With MLL partial Tandem Duplication Are Sensitive To Pharmacological Inhibition Of The H3K79 Methyltransferase DOT1L

Michael W.M. Kühn, MD, Michael Hadler, MSc, Scott R. Daigle, PhD, Chun-Wei Chen, PhD, Amit U. Sinha, PhD, Andrei V. Krivtsov, PhD, Edward J. Olhava, PhD, Michael A. Caligiuri, MD, James E Bradner, MD, Roy M. Pollock, PhD, Scott A. Armstrong, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 1256.
https://doi.org/10.1182/blood.V122.21.1256.1256
Published: 2013
Journal Articles

Preclinical Characterization of a Potent, Selective Inhibitor of the Protein Methyltransferase DOT1L for Use in the Treatment of MLL -Rearranged Leukemia.

Roy M Pollock, PhD, Scott R Daigle, Carly A Therkelsen, Aravind Basavapathruni, PhD, Lei Jin, PhD, Christina J Allain, Christine R Klaus, Alejandra Raimondi, PhD, Margaret Porter Scott, PhD, Richard Chesworth, DPhil, Mikel P Moyer, PhD, Robert A Copeland, PhD, Victoria M Richon, PhD, Edward J Olhava, PhD
Journal: Blood
Blood (2012) 120 (21): 2379.
https://doi.org/10.1182/blood.V120.21.2379.2379
Published: 2012
Journal Articles

Abrogation of MLL-AF10 and CALM-AF10 Mediated Transformation Through Genetic Inactivation or Pharmacological Inhibition of the H3K79 Methyltransferase DOT1L.

Liying Chen, Aniruddha J Deshpande, Deepti Banka, Bernt Kathrin, Stuart Dias, Christian Buske, MD, Edward J Olhava, PhD, Scott R Daigle, Victoria M Richon, PhD, Roy M Pollock, PhD, Scott A. Armstrong, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 2384.
https://doi.org/10.1182/blood.V120.21.2384.2384
Published: 2012
Journal Articles

MLL-AF6 Mediated Transformation Is Dependent On the H3K79 Methyl-transferase Dot1l

Aniruddha J Deshpande, Liying Chen, Maurizio Fazio, Amit U. Sinha, Kathrin M Bernt, MD, Deepti Banka, Stuart Dias, Edward J Olhava, PhD, Scott R Daigle, Victoria M Richon, PhD, Roy M Pollock, PhD, Scott A. Armstrong, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 3502.
https://doi.org/10.1182/blood.V120.21.3502.3502
Published: 2012
Journal Articles

Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor

Roy M Pollock, PhD, Scott R Daigle, Edward J Olhava, PhD, Carly A Therkelsen, Christina R Majer, Jeffrey Song, Christina J Allain, Christopher J Sneeringer, L. Danielle Johnston, Margaret Porter Scott, PhD, Lei Jin, PhD, Kevin W Kuntz, PhD, Richard Chesworth, DPhil, Mikel P Moyer, PhD, Kathrin M Bernt, MD, Scott Armstrong, MD, PhD, Robert A Copeland, PhD, Victoria M Richon, PhD
Journal: Blood
Blood (2010) 116 (21): 780.
https://doi.org/10.1182/blood.V116.21.780.780
Published: 2010